share_log

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22

Morgan Stanley Maintains Underweight on Veracyte, Lowers Price Target to $22

摩根士丹利維持對Veracyte的減持,將目標股價下調至22美元
Benzinga ·  2023/11/10 09:26

Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and lowers the price target from $23 to $22.

摩根士丹利分析師特哈斯·薩萬特維持Veracyte(納斯達克股票代碼:VCYT)的減持,並將目標股價從23美元下調至22美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論